Alx oncology announces encouraging final results from phase 1 trial evaluating evorpacept in combination with standard-of-care treatment in patients with b-cell non-hodgkin lymphoma

- data to be presented at aacr 2025 annual meeting suggest the combination of alx oncology's investigational cd47-blocker, evorpacept, plus rituximab and lenalidomide (r 2 ) was well-tolerated and demonstrated promising anti-tumor activity
ALXO Ratings Summary
ALXO Quant Ranking